PerkinElmer raises Q4 2021 outlook: adj. EPS at least $2.40, non-COVID organic growth ~10%

REVVITY, INC.

2021-FY EPS reported $8.08 revenue$3,827,808,000

Q4 2021 adjusted EPS expected at least $2.40, above prior guidance.
Q4 non-COVID organic growth ~10%; full-year 2021 non-COVID organic growth ~16%.
Q4 COVID-related revenue ~$320M; full-year COVID revenue over $1.5B.
Full-year 2021 total revenue ~$5.0B: Diagnostics ~$2.9B, Discovery & Analytical Solutions ~$2.1B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.